U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

ALK Gene Rearrangement

MedGen UID:
1380680
•Concept ID:
C4068350
•
Finding
Synonyms: ALK Rearrangement; Anaplastic Lymphoma Kinase Gene Rearrangement; Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Rearrangement; CD246 Gene Rearrangement

Definition

A molecular abnormality indicating rearrangement of the ALK gene. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVALK Gene Rearrangement

Professional guidelines

PubMed

Management of leptomeningeal metastases in non-small cell lung cancer.
Patil S, Rathnum KK
Indian J Cancer 2019 Nov;56(Supplement):S1-S9. doi: 10.4103/ijc.IJC_74_19. PMID: 31793437
ALK inhibitors in the treatment of advanced NSCLC.
Gridelli C, Peters S, Sgambato A, Casaluce F, Adjei AA, Ciardiello F
Cancer Treat Rev 2014 Mar;40(2):300-6. Epub 2013 Aug 7 doi: 10.1016/j.ctrv.2013.07.002. PMID: 23931927
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C
Target Oncol 2013 Mar;8(1):55-67. Epub 2013 Jan 17 doi: 10.1007/s11523-012-0250-9. PMID: 23325296

Recent clinical studies

Etiology

Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
Zhao D, Chen J, Chu M, Long X, Wang J
Drug Des Devel Ther 2020;14:1663-1681. Epub 2020 Apr 30 doi: 10.2147/DDDT.S249098. PMID: 32431491Free PMC Article
Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H, Wang Y, Zhang H, Han Y, Li Q, Ye Z
Clin Radiol 2020 Jul;75(7):562.e21-562.e29. Epub 2020 Apr 16 doi: 10.1016/j.crad.2020.03.026. PMID: 32307109
ALCL by any other name: the many facets of anaplastic large cell lymphoma.
Irshaid L, Xu ML
Pathology 2020 Jan;52(1):100-110. Epub 2019 Nov 6 doi: 10.1016/j.pathol.2019.09.007. PMID: 31706671
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
Kerr KM, López-Ríos F
Ann Oncol 2016 Sep;27 Suppl 3:iii16-iii24. doi: 10.1093/annonc/mdw302. PMID: 27573752
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS, Kang G, Sohn JH
Int J Biol Markers 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218. PMID: 27338643

Diagnosis

ALK Translocation in ALK-Positive Mesenchymal Tumors: Diagnostic and Therapeutic Insights.
Jung M, Moon KC, Bae J, Kim TM, Kim M, Jeon YK, Lee C
Arch Pathol Lab Med 2022 Dec 1;146(12):1460-1470. doi: 10.5858/arpa.2021-0330-OA. PMID: 35438749
Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
Zhao D, Chen J, Chu M, Long X, Wang J
Drug Des Devel Ther 2020;14:1663-1681. Epub 2020 Apr 30 doi: 10.2147/DDDT.S249098. PMID: 32431491Free PMC Article
ALCL by any other name: the many facets of anaplastic large cell lymphoma.
Irshaid L, Xu ML
Pathology 2020 Jan;52(1):100-110. Epub 2019 Nov 6 doi: 10.1016/j.pathol.2019.09.007. PMID: 31706671
Precision medicine in NSCLC and pathology: how does ALK fit in the pathway?
Kerr KM, López-Ríos F
Ann Oncol 2016 Sep;27 Suppl 3:iii16-iii24. doi: 10.1093/annonc/mdw302. PMID: 27573752
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS, Kang G, Sohn JH
Int J Biol Markers 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218. PMID: 27338643

Therapy

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R
Nat Commun 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w. PMID: 33627640Free PMC Article
Pharmacokinetic-Based Drug-Drug Interactions with Anaplastic Lymphoma Kinase Inhibitors: A Review.
Zhao D, Chen J, Chu M, Long X, Wang J
Drug Des Devel Ther 2020;14:1663-1681. Epub 2020 Apr 30 doi: 10.2147/DDDT.S249098. PMID: 32431491Free PMC Article
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
Katayama R
Cancer Sci 2018 Mar;109(3):572-580. Epub 2018 Feb 15 doi: 10.1111/cas.13504. PMID: 29336091Free PMC Article
Future options for ALK-positive non-small cell lung cancer.
Iacono D, Chiari R, Metro G, Bennati C, Bellezza G, Cenci M, Ricciuti B, Sidoni A, Baglivo S, Minotti V, Crinò L
Lung Cancer 2015 Mar;87(3):211-9. Epub 2015 Jan 3 doi: 10.1016/j.lungcan.2014.12.017. PMID: 25601484
ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.
Casaluce F, Sgambato A, Maione P, Rossi A, Ferrara C, Napolitano A, Palazzolo G, Ciardiello F, Gridelli C
Target Oncol 2013 Mar;8(1):55-67. Epub 2013 Jan 17 doi: 10.1007/s11523-012-0250-9. PMID: 23325296

Prognosis

Artificial Intelligence-Powered Prediction of ALK Gene Rearrangement in Patients With Non-Small-Cell Lung Cancer.
Terada Y, Takahashi T, Hayakawa T, Ono A, Kawata T, Isaka M, Muramatsu K, Tone K, Kodama H, Imai T, Notsu A, Mori K, Ohde Y, Nakajima T, Sugino T, Takahashi T
JCO Clin Cancer Inform 2022 Sep;6:e2200070. doi: 10.1200/CCI.22.00070. PMID: 36162012
Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H, Wang Y, Zhang H, Han Y, Li Q, Ye Z
Clin Radiol 2020 Jul;75(7):562.e21-562.e29. Epub 2020 Apr 16 doi: 10.1016/j.crad.2020.03.026. PMID: 32307109
ALCL by any other name: the many facets of anaplastic large cell lymphoma.
Irshaid L, Xu ML
Pathology 2020 Jan;52(1):100-110. Epub 2019 Nov 6 doi: 10.1016/j.pathol.2019.09.007. PMID: 31706671
Management of leptomeningeal metastases in non-small cell lung cancer.
Patil S, Rathnum KK
Indian J Cancer 2019 Nov;56(Supplement):S1-S9. doi: 10.4103/ijc.IJC_74_19. PMID: 31793437
Advances in the clinicopathological and molecular classification of cutaneous mesenchymal neoplasms.
Costigan DC, Doyle LA
Histopathology 2016 May;68(6):776-95. Epub 2016 Mar 1 doi: 10.1111/his.12930. PMID: 26763770

Clinical prediction guides

Artificial Intelligence-Powered Prediction of ALK Gene Rearrangement in Patients With Non-Small-Cell Lung Cancer.
Terada Y, Takahashi T, Hayakawa T, Ono A, Kawata T, Isaka M, Muramatsu K, Tone K, Kodama H, Imai T, Notsu A, Mori K, Ohde Y, Nakajima T, Sugino T, Takahashi T
JCO Clin Cancer Inform 2022 Sep;6:e2200070. doi: 10.1200/CCI.22.00070. PMID: 36162012
Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer.
Mizuta H, Okada K, Araki M, Adachi J, Takemoto A, Kutkowska J, Maruyama K, Yanagitani N, Oh-Hara T, Watanabe K, Tamai K, Friboulet L, Katayama K, Ma B, Sasakura Y, Sagae Y, Kukimoto-Niino M, Shirouzu M, Takagi S, Simizu S, Nishio M, Okuno Y, Fujita N, Katayama R
Nat Commun 2021 Feb 24;12(1):1261. doi: 10.1038/s41467-021-21396-w. PMID: 33627640Free PMC Article
Preoperative CT features for prediction of ALK gene rearrangement in lung adenocarcinomas.
Wang H, Wang Y, Zhang H, Han Y, Li Q, Ye Z
Clin Radiol 2020 Jul;75(7):562.e21-562.e29. Epub 2020 Apr 16 doi: 10.1016/j.crad.2020.03.026. PMID: 32307109
Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
Katayama R
Cancer Sci 2018 Mar;109(3):572-580. Epub 2018 Feb 15 doi: 10.1111/cas.13504. PMID: 29336091Free PMC Article
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS, Kang G, Sohn JH
Int J Biol Markers 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218. PMID: 27338643

Recent systematic reviews

First-line treatments for patients with advanced ALK gene rearrangements in NSCLC: a systematic review and network meta-analysis.
Tao J, Zheng C, Zhang C, Zhou L, Liu Z, Zhou Y, Huang X, Lin L, Zhai L
J Int Med Res 2022 Nov;50(11):3000605221132703. doi: 10.1177/03000605221132703. PMID: 36380511Free PMC Article
Effect of ALK-inhibitors in the treatment of non-small cell lung cancer: a systematic review and meta-analysis.
Li G, Dai WR, Shao FC
Eur Rev Med Pharmacol Sci 2017 Aug;21(15):3496-3503. PMID: 28829490
Efficacy of D5F3 IHC for detecting ALK gene rearrangement in NSCLC patients: a systematic review and meta-analysis.
Ma H, Yao WX, Huang L, Jin SH, Liu DH, Liu Y, Tian X, Tian JH, Zhou JG
Oncotarget 2016 Oct 25;7(43):70128-70142. doi: 10.18632/oncotarget.11806. PMID: 27602773Free PMC Article
ALK immunohistochemistry for ALK gene rearrangement screening in non-small cell lung cancer: a systematic review and meta-analysis.
Pyo JS, Kang G, Sohn JH
Int J Biol Markers 2016 Dec 23;31(4):e413-e421. doi: 10.5301/jbm.5000218. PMID: 27338643

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...